Ironwood Pharmaceuticals (IRWD) Amortization of Deferred Charges (2013 - 2026)

Ironwood Pharmaceuticals has reported Amortization of Deferred Charges for 14 years, with the latest figure at $444000.0 in Q1 2026.

• Quarterly Amortization of Deferred Charges rose 8.56% year-over-year to $444000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 8.43% YoY) and the FY2025 annual result came in at $1.7 million, up 8.34% from the prior year.
• Amortization of Deferred Charges climbed to $444000.0 in Q1 2026 per IRWD's latest filing, from $435000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $587000.0 in Q4 2023 and troughed at $378000.0 in Q1 2024.
• A 5-year average of $447235.3 and a median of $418000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2022 and 2023: Amortization of Deferred Charges plunged 93.49% in 2022, then soared 46.75% in 2023.
• Over 5 years, Amortization of Deferred Charges stood at $400000.0 in 2022, then jumped by 46.75% to $587000.0 in 2023, then plunged by 31.52% to $402000.0 in 2024, then advanced by 8.21% to $435000.0 in 2025, then climbed by 2.07% to $444000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $444000.0, $435000.0, and $426000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.